Clobromazolam Stats & Data

Phenazolam is the same compound as clobromazolam; it first appeared on the market circa 2016 and has no approved medical use. Forum meta-reports consistently place its potency in the sub‑milligram range, with ~0.25 mg often compared to a typical anxiolytic dose range of diazepam; avoid any pressed tablets claiming multi‑milligram doses. Onset is notably slow for a triazolobenzodiazepine (often 1–2 h, sometimes 3 h), which greatly increases redosing risk and blackout potential. Volumetric dosing is essential: dissolve a known amount in a measured volume (e.g., 1 mg in 10–20 mL ethanol/propylene glycol), mix thoroughly, and measure doses with an oral syringe; do not eyeball powders or shave tablets. Wait a full 3–4 hours before considering any redose due to delayed peak and amnesia. Multiple reports describe next‑day impairment lasting well beyond the perceived high; avoid driving or hazardous tasks for at least 24 h after dosing. Novel benzodiazepines are widely found in counterfeit ‘Xanax/Valium’-type tablets and in non‑benzo samples; mislabeling and extreme dose variability have been repeatedly documented by drug‑checking and early warning systems — treat unknown tablets/solutions as suspect and test where possible. Combining with opioids, alcohol, GHB/GBL, dissociatives, or gabapentinoids is the main cause of life‑threatening events; treat these as hard contraindications. Naloxone reverses opioids but not benzodiazepines; always prioritize airway and breathing in mixed‑drug poisonings until help arrives. Flumazenil can precipitate acute withdrawal and seizures in dependent users and should only be given in a clinical setting by trained staff. Because supply may include bromazolam or other benzos mis‑sold as clobromazolam, assume mislabeling until proven otherwise and start at the absolute minimum dose.